Cargando…

Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization

Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Borriello, Francesco, Pietrasanta, Carlo, Lai, Jacqueline C. Y., Walsh, Lois M., Sharma, Pankaj, O’Driscoll, David N., Ramirez, Juan, Brightman, Spencer, Pugni, Lorenza, Mosca, Fabio, Burkhart, David J., Dowling, David J., Levy, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732947/
https://www.ncbi.nlm.nih.gov/pubmed/29312305
http://dx.doi.org/10.3389/fimmu.2017.01772
_version_ 1783286802957729792
author Borriello, Francesco
Pietrasanta, Carlo
Lai, Jacqueline C. Y.
Walsh, Lois M.
Sharma, Pankaj
O’Driscoll, David N.
Ramirez, Juan
Brightman, Spencer
Pugni, Lorenza
Mosca, Fabio
Burkhart, David J.
Dowling, David J.
Levy, Ofer
author_facet Borriello, Francesco
Pietrasanta, Carlo
Lai, Jacqueline C. Y.
Walsh, Lois M.
Sharma, Pankaj
O’Driscoll, David N.
Ramirez, Juan
Brightman, Spencer
Pugni, Lorenza
Mosca, Fabio
Burkhart, David J.
Dowling, David J.
Levy, Ofer
author_sort Borriello, Francesco
collection PubMed
description Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvant candidates for early life immunization. We employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a screening of pattern recognition receptor agonists and found that the stimulator of interferon genes ligand 2′3′-cGAMP (hereafter cGAMP) induces a comparable expression of surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to investigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum (Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody subclass associated with the development of IFNγ-driven type 1 immunity in vivo and endowed with higher effector functions, by 42 days of life. Highlighting the amenability for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted IFNγ production by CD4(+) T cells and increased the proportions and absolute numbers of CD4(+) CXCR5(+) PD-1(+) T follicular helper and germinal center (GC) GL-7(+) CD138(+) B cells, suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP when formulated with alum may represent an effective adjuvantation system to foster humoral and cellular aspects of type 1 immunity for early life immunization.
format Online
Article
Text
id pubmed-5732947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57329472018-01-08 Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization Borriello, Francesco Pietrasanta, Carlo Lai, Jacqueline C. Y. Walsh, Lois M. Sharma, Pankaj O’Driscoll, David N. Ramirez, Juan Brightman, Spencer Pugni, Lorenza Mosca, Fabio Burkhart, David J. Dowling, David J. Levy, Ofer Front Immunol Immunology Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvant candidates for early life immunization. We employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a screening of pattern recognition receptor agonists and found that the stimulator of interferon genes ligand 2′3′-cGAMP (hereafter cGAMP) induces a comparable expression of surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to investigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum (Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody subclass associated with the development of IFNγ-driven type 1 immunity in vivo and endowed with higher effector functions, by 42 days of life. Highlighting the amenability for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted IFNγ production by CD4(+) T cells and increased the proportions and absolute numbers of CD4(+) CXCR5(+) PD-1(+) T follicular helper and germinal center (GC) GL-7(+) CD138(+) B cells, suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP when formulated with alum may represent an effective adjuvantation system to foster humoral and cellular aspects of type 1 immunity for early life immunization. Frontiers Media S.A. 2017-12-12 /pmc/articles/PMC5732947/ /pubmed/29312305 http://dx.doi.org/10.3389/fimmu.2017.01772 Text en Copyright © 2017 Borriello, Pietrasanta, Lai, Walsh, Sharma, O’Driscoll, Ramirez, Brightman, Pugni, Mosca, Burkhart, Dowling and Levy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Borriello, Francesco
Pietrasanta, Carlo
Lai, Jacqueline C. Y.
Walsh, Lois M.
Sharma, Pankaj
O’Driscoll, David N.
Ramirez, Juan
Brightman, Spencer
Pugni, Lorenza
Mosca, Fabio
Burkhart, David J.
Dowling, David J.
Levy, Ofer
Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title_full Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title_fullStr Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title_full_unstemmed Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title_short Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
title_sort identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732947/
https://www.ncbi.nlm.nih.gov/pubmed/29312305
http://dx.doi.org/10.3389/fimmu.2017.01772
work_keys_str_mv AT borriellofrancesco identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT pietrasantacarlo identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT laijacquelinecy identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT walshloism identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT sharmapankaj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT odriscolldavidn identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT ramirezjuan identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT brightmanspencer identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT pugnilorenza identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT moscafabio identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT burkhartdavidj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT dowlingdavidj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization
AT levyofer identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization